Supercharged immune cells take on melanoma in new combo therapy trial

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 170 adults aged 18 to 72 who have already tried at least one other treatment will take part. Participants receive chemotherapy, then their own lab-grown immune cells plus pembrolizumab (for some), followed by IL-2 to boost the cells. The goal is to see if the combination is safe and works better than TIL therapy alone.